"This data gives patients the option to benefit from esketamine treatment either with or without an antidepressant," said ...

The US drugs regulator has approved the sale of a new nasal spray to treat depression. Manufacturer Janssen says Esketamine can ... cost up to $885 (£673) per treatment. In a statement, Janssen ...

More information: Jennifer Kern Sliwa et al, Effects of esketamine nasal spray on depressive symptom severity in adults with ...

Janssen, which is Johnson & Johnson’s pharma unit, submitted a filing to the European Medicines Agency for esketamine nasal spray, which is designed to help people with treatment-resistant ...

Five phase 3 studies of esketamine nasal spray in patients with treatment-resistant depression revealed that the latter plus a newly initiated oral antidepressant, compared to a placebo plus the ...

Read on to know all about this treatment option ... study published in the American Journal of Psychiatry, a new esketamine nasal spray can effectively treat depression. Snoring is not a minor ...

The FDA updated a warning on the label of esketamine nasal spray (Spravato) about the long-term cognitive and memory impairments that have been reported with ketamine misuse or abuse. New 3-year ...

The nasal spray is now undergoing phase three trials before it can be licensed for treatment. There were no reports of esketamine dependence or misuse in the trial but the authors warn that more ...

When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers.

Presentations include new data supporting the safety and efficacy of SPRAVATO® (esketamine) CIII nasal spray and the Company's innovative portfolio of long-acting injectables (LAIs) for ...